Balancing Treatment Decisions With a Patient's Quality of Life
- Dr. George Yaghmour, a hematologist faculty member at USC Norris Cancer Center, emphasizes that treatment for CLL begins only when symptoms or lab findings demand it, and once that point is reached, quality of life becomes central — patients want effective control of the disease without constant hospital visits or burdensome side effects.
- Choosing a treatment approach is a balance of three factors: whether treatment is truly needed, whether a patient prefers to avoid infusion centers, and how well they can tolerate side effects from options like venetoclax or BTK inhibitors.
- Modern CLL therapies offer flexible paths — from all‑oral regimens to time‑limited combinations — allowing patients and doctors to select an approach that controls the disease while preserving daily life, comfort, and independence.
“We either just don’t have to do anything and the patient has to be just monitored, and that’s the watch-and-wait period,” Dr. George Yaghmour, a hematologist faculty member at USC Norris Cancer Center in Los Angeles, tells SurvivorNet.
Read MoreWhen Symptoms Signal It’s Time for Treatment
Patients, along with their medical teams, monitor and report any symptoms that may arise, then determine the next steps based on the severity of those symptoms and what they mean. “When we get to the point that we start having issues and symptoms from the disease, that is the point when we must get those symptoms controlled,” Dr. Yaghmour explains.He points to constitutional symptoms sometimes referred to as “B symptoms” — though it’s worth clarifying what that term technically refers to. The classic B-symptom triad in blood cancers like CLL is fever, drenching night sweats, and unintentional weight loss.
Dr. Yaghmour also describes low energy and appetite loss, related constitutional symptoms doctors consider when assessing the disease’s impact on a patient’s health.
Once a patient has a high enough disease burden or symptom load to need treatment, quality of life becomes a central part of the decision.
“They don’t want to be in the hospital getting IVs all the time around other cancer patients,” Dr. Yaghmour says. “They don’t want to be having a lot of chemo pills, which give them too many side effects and toxicity.”
WATCH: Physical Symptoms Are Usually Seen in Advanced Stages of CLL
A Three-Factor Balancing Act
According to Dr. Yaghmour, choosing a treatment approach comes down to three main factors patients weigh:
- The need for treatment itself — has the disease reached a point where symptoms or lab findings require intervention?
- Avoiding infusion centers and hospital visits — many patients strongly prefer to avoid IV treatment. “The majority of patients say, ‘I don’t want IV treatment,'” he notes.
- The ability to tolerate medication without significant side effects.
Dr. Yaghmour adds that patient preferences vary widely. Some patients want an all-oral regimen and are done; others are comfortable combining a pill with an IV infusion if it means a defined treatment period.
“Some people still say, ‘I would get the IV and the pills. If I finish in six months to one year, I’m done,'” Dr. Yaghmour says. This reflects the real options available today — fixed-duration regimens combining an IV antibody like obinutuzumab (Gazyva) with an oral BCL-2 inhibitor venetoclax (Venclexta) have become an established, effective first-line approach.
Expert Resources for CLL Patients
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- Chronic Lymphocytic Leukemia (CLL): How Can Pirtobrutinib Fit Into My Treatment Plan?
- Do I Need A Stem Cell Transplant For CLL?
- Changing the Way CLL is Treated: What are BTK Inhibitors?
- After the Initial CLL Diagnosis: The First Conversation
Managing Side Effects: Venetoclax (BCL-2 Inhibitor)
For patients on venetoclax, Dr. Yaghmour says the main things his team monitors are infection risk, low blood counts, and the potential need for a transfusion. Patients also typically spend a short period in the hospital early in treatment.
“They need to be in the hospital for a short period of time to titrate the dose slightly up,” he explains, “and basically, otherwise, it is a very well-tolerated treatment. Sometimes they get an allergic reaction.”
The hospital stay reflects a well-established safety protocol: venetoclax is started at a low dose and gradually increased over five weeks specifically to reduce the risk of tumor lysis syndrome (TLS), a condition where cancer cells break down too quickly. Patients at higher risk for TLS may be monitored in the hospital during the first doses of this ramp-up period, with bloodwork checked closely for several hours after each dose increase.
Managing Side Effects: BTK Inhibitors
BTK inhibitors (Bruton’s tyrosine kinase inhibitors) have evolved across several generations, each with a somewhat different side effect profile. These targeted treatments are changing the game in CLL survival.
“There is this first generation, second generation, and third generation,” Dr. Yaghmour says.
WATCH: How BTK Inhibitors Can Improve the Treatment of Chronic Lymphocytic Leukemia
“The toxicity profile will generally include nausea, vomiting, and headaches. We monitor for blood clots or thrombosis risk, arrhythmia, and blood pressure… sometimes we monitor for risk of infection symptoms as well.”
This generational breakdown matches how the drug class has developed. The first-generation BTK inhibitor, ibrutinib (Imbruvica), is effective but has been most closely linked to cardiovascular side effects such as irregular heart rhythm (atrial fibrillation) and high blood pressure.
Second-generation options, including acalabrutinib (Calquence) and zanubrutinib (Brukinsa), were developed to be more selective and have shown lower rates of these cardiovascular complications in head-to-head studies. A newer, non-covalent option, pirtobrutinib (Jaypirca), is sometimes referred to as a third-generation BTK inhibitor, and early evidence suggests it may carry an even lower cardiovascular risk, though this is still being studied.
CLL Treatments and Personal Lifestyle Priorities
Essentially, Dr. Yaghmour’s core message is that treating CLL is not just about controlling the disease — it’s about doing so in a way that fits each patient’s life and priorities.
Whether that means an all-oral regimen, a time-limited combination with an infusion, or careful side-effect monitoring along the way, the goal is the same: Control the disease without letting the treatment itself take over the patient’s quality of life.
Learn more about SurvivorNet's rigorous medical review process.
